Cargando…
Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis
We conducted a meta-analysis of published data to update and estimate the prevalence of HPV in ovarian cancer. A comprehensive literature search was performed according to the PRISMA guidelines. Eligible articles published from 1989 until 2020 by searching Web of Sciences, Pubmed, Embase, and the Co...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346400/ https://www.ncbi.nlm.nih.gov/pubmed/34086102 http://dx.doi.org/10.1007/s10096-021-04282-7 |
_version_ | 1783734862067269632 |
---|---|
author | Cherif, Soumia Amine, Abdessamad Thies, Sarah Taube, Eliane T. Braicu, Elena Ioana Sehouli, Jalid Kaufmann, Andreas M. |
author_facet | Cherif, Soumia Amine, Abdessamad Thies, Sarah Taube, Eliane T. Braicu, Elena Ioana Sehouli, Jalid Kaufmann, Andreas M. |
author_sort | Cherif, Soumia |
collection | PubMed |
description | We conducted a meta-analysis of published data to update and estimate the prevalence of HPV in ovarian cancer. A comprehensive literature search was performed according to the PRISMA guidelines. Eligible articles published from 1989 until 2020 by searching Web of Sciences, Pubmed, Embase, and the Cochrane Library Central databases were gathered. A pooled estimation of HPV prevalence with a 95% confidence interval (CI) was calculated based on a random effect model. Quantitative assessment of heterogeneity was explored using Cochrane test and I(2). Additionally, publication bias, sensitivity, meta-regression, and subgroup analyses were also performed. Twenty-nine studies involving 2280 patients with ovarian cancer were included. The statistical heterogeneity was high (I(2) = 88%, P<0.0001). The pooled prevalence of HPV in ovarian cancer cases was 15.9% (95% CI, 11–22). In subgroup analyses, the highest prevalence of HPV was reported by studies from Asia (30.9%; 95% CI, 20–44) and Eastern Europe (29.3%; 95% CI, 4.4–78). Furthermore, the most frequently detected HPV genotype was HPV16 (54%; 95% CI, 27.9–55), followed by HPV18 (23.2%; 95% CI, 18.8–28.2). Our meta-analysis suggests a great difference in the prevalence of HPV detected in ovarian cancer by different studies, which is not seen in strongly HPV-associated cancers such as cervical cancer. However, the prevalence varied markedly by geographic region. Considering the substantial heterogeneity found, more studies with control groups and precise assays measuring HPV mRNA expression are needed to further evaluate the link and causative aetiology between HPV and ovarian cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10096-021-04282-7. |
format | Online Article Text |
id | pubmed-8346400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-83464002021-08-20 Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis Cherif, Soumia Amine, Abdessamad Thies, Sarah Taube, Eliane T. Braicu, Elena Ioana Sehouli, Jalid Kaufmann, Andreas M. Eur J Clin Microbiol Infect Dis Review We conducted a meta-analysis of published data to update and estimate the prevalence of HPV in ovarian cancer. A comprehensive literature search was performed according to the PRISMA guidelines. Eligible articles published from 1989 until 2020 by searching Web of Sciences, Pubmed, Embase, and the Cochrane Library Central databases were gathered. A pooled estimation of HPV prevalence with a 95% confidence interval (CI) was calculated based on a random effect model. Quantitative assessment of heterogeneity was explored using Cochrane test and I(2). Additionally, publication bias, sensitivity, meta-regression, and subgroup analyses were also performed. Twenty-nine studies involving 2280 patients with ovarian cancer were included. The statistical heterogeneity was high (I(2) = 88%, P<0.0001). The pooled prevalence of HPV in ovarian cancer cases was 15.9% (95% CI, 11–22). In subgroup analyses, the highest prevalence of HPV was reported by studies from Asia (30.9%; 95% CI, 20–44) and Eastern Europe (29.3%; 95% CI, 4.4–78). Furthermore, the most frequently detected HPV genotype was HPV16 (54%; 95% CI, 27.9–55), followed by HPV18 (23.2%; 95% CI, 18.8–28.2). Our meta-analysis suggests a great difference in the prevalence of HPV detected in ovarian cancer by different studies, which is not seen in strongly HPV-associated cancers such as cervical cancer. However, the prevalence varied markedly by geographic region. Considering the substantial heterogeneity found, more studies with control groups and precise assays measuring HPV mRNA expression are needed to further evaluate the link and causative aetiology between HPV and ovarian cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10096-021-04282-7. Springer Berlin Heidelberg 2021-06-04 2021 /pmc/articles/PMC8346400/ /pubmed/34086102 http://dx.doi.org/10.1007/s10096-021-04282-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Cherif, Soumia Amine, Abdessamad Thies, Sarah Taube, Eliane T. Braicu, Elena Ioana Sehouli, Jalid Kaufmann, Andreas M. Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis |
title | Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis |
title_full | Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis |
title_fullStr | Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis |
title_full_unstemmed | Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis |
title_short | Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis |
title_sort | prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346400/ https://www.ncbi.nlm.nih.gov/pubmed/34086102 http://dx.doi.org/10.1007/s10096-021-04282-7 |
work_keys_str_mv | AT cherifsoumia prevalenceofhumanpapillomavirusdetectioninovariancancerametaanalysis AT amineabdessamad prevalenceofhumanpapillomavirusdetectioninovariancancerametaanalysis AT thiessarah prevalenceofhumanpapillomavirusdetectioninovariancancerametaanalysis AT taubeelianet prevalenceofhumanpapillomavirusdetectioninovariancancerametaanalysis AT braicuelenaioana prevalenceofhumanpapillomavirusdetectioninovariancancerametaanalysis AT sehoulijalid prevalenceofhumanpapillomavirusdetectioninovariancancerametaanalysis AT kaufmannandreasm prevalenceofhumanpapillomavirusdetectioninovariancancerametaanalysis |